Kevin Gorman, Neurocrine Biosciences CEO
Neurocrine’s depression drug passes Phase 2 trial
Neurocrine Biosciences reported that its pill for major depressive disorder reduced scores on a depression severity scale at about one month in a Phase 2 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
